NCT05135715 2024-02-20
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
RemeGen Co., Ltd.
Phase 2 Unknown
RemeGen Co., Ltd.
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Fudan University